Mandel Bencard Allergie (Almond)

The almond extract provides specific almond allergens that bind to IgE antibodies on mast cells in the skin. This binding triggers localized degranulation, releasing histamine and other mediators that cause a wheal‑and‑flare reaction, indicating the presence of almond‑specific IgE.

The dose of Mandel Bencard Allergie is determined by the prescribing clinician based on the testing protocol, patient age, and clinical context. No fixed dosing regimen is provided publicly; the healthcare professional selects the appropriate concentration for the skin test.

Safety data for Mandel Bencard Allergie in pregnancy or lactation are limited. Because it is an intraepidermal diagnostic extract, the decision to use it should be made by a qualified clinician after weighing potential benefits against any unknown risks.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mandel Bencard Allergie is a standardized intraepidermal extract designed for direct skin testing, offering rapid visual results. Compared with serum‑based specific IgE assays, it provides a functional assessment of skin reactivity but requires a controlled clinical environment and emergency preparedness for possible systemic reactions.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and allow it to reach room temperature briefly if required by the testing protocol.

Mandel Bencard Allergie is administered by intraepidermal (skin prick or intradermal) injection performed by a trained healthcare professional. A small amount of the extract is placed on the skin and introduced into the epidermis, after which the test site is observed for a wheal‑and‑flare reaction.

The most serious risks include systemic anaphylaxis, severe bronchospasm, and angioedema. These reactions can occur rapidly after administration, so patients should be monitored for at least 30 minutes and emergency medications such as epinephrine should be readily available.

Patients with a known severe almond allergy, uncontrolled asthma, or a history of anaphylaxis to almond should not undergo testing with this extract. Additionally, individuals taking beta‑blockers or those unable to tolerate potential systemic reactions should be evaluated carefully before use.